Sean Lee
Stock Analyst at HC Wainwright & Co.
(1.61)
# 1101
Out of 5,298 analysts
103
Total ratings
33.87%
Success rate
18.85%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
CTSO CytoSorbents | Reiterates: Neutral | 1 1 | 0.94 | 6.38% | 12 | Apr 3, 2025 | |
MNPR Monopar Therapeutics | Reiterates: Buy | 40 40 | 29.95 | 33.56% | 10 | Apr 1, 2025 | |
PSTV Plus Therapeutics | Maintains: Buy | 8 6 | 0.82 | 570.73% | 11 | Mar 28, 2025 | |
CRVS Corvus Pharma | Reiterates: Buy | 11 11 | 2.81 | 291.46% | 3 | Mar 26, 2025 | |
VSTM Verastem | Maintains: Strong Buy | 7 10 | 5.31 | 88.32% | 13 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 8 10 | 4.42 | 114.93% | 5 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 20 20 | 10.03 | 99.4% | 11 | Jan 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 1 5 | n/a | n/a | 4 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 4 1 | n/a | n/a | 14 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 20 20 | 0.7 | 2757.14% | 4 | Jul 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 12 6 | 2.09 | 187.08% | 7 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 5 | n/a | n/a | 7 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 30 | 1.08 | 2677.78% | 1 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 1 | Mar 19, 2021 |